Tirzepatide (Mounjaro) has rapidly become one of the most discussed medications in diabetes and obesity medicine. Its dual GIP/GLP-1 receptor agonist mechanism produces unprecedented reductions in blood sugar and body weight. But what does the evidence say about its cardiovascular effects — and how does it compare to semaglutide? How Tirzepatide Works Unlike semaglutide, which…
GLP-1 receptor agonists were originally developed to lower blood sugar. What researchers discovered in subsequent cardiovascular outcome trials was something far more significant: these medications actively protect the heart, reduce the risk of stroke, and lower cardiovascular mortality — benefits that extend well beyond glucose control. The Landmark Cardiovascular Outcome Trials Trial Drug Key Finding…
A large study published this month in Nature Medicine helps answer a question many patients and clinicians have been asking: Do the newer diabetes medications, semaglutide and tirzepatide, actually protect the heart? The study demonstrates that both medications provide cardiovascular protection through solid real-world evidence. [1] In this large real-world observational study, researchers from Mass…
English 
Urdu